Information Provided By: 
Fly News Breaks for September 30, 2019
FATE
Sep 30, 2019 | 16:17 EDT
Stifel analyst Benjamin Burnett initiated Fate Therapeutics with a Buy rating and $27 price target, citing his expectation that FT500 data later this year will validate the safety of the company's NK cell platform and that FT516 will show differentiated efficacy in acute myeloid leukemia. While he thinks he is assigning higher than consensus odds for the success of FT516, Burnett said he is more cautious on the prospects of FT500 being able to generate compelling efficacy data in solid tumors.
News For FATE From the Last 2 Days
FATE
Apr 18, 2024 | 17:52 EDT
Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGSMetropolitan... To see the rest of the story go to thefly.com. See Story Here
